"Schulen der Macht?" : Governance Schools in Deutschland

„Governance Schools“ lassen sich als multidisziplinäre, praxisorientierte Ausbildungseinrichtungen verstehen, die Studierende unmittelbar für den Berufsalltag in einem weit verstandenen Feld von „Politik“ in Staat, Wirtschaft und Zivilgesellschaft qualifizieren wollen. Bildungspolitisch stellen sie keine Konkurrenz, sondern eine Ergänzung zu den stärker wissenschaftlich-disziplinären Angeboten der öffentlichen Universitäten dar und können dabei allenfalls den Anspruch erheben, ein wenig „Hefe“ im derzeit – aus guten Gründen – stark gärenden „Teig“ der deutschen Bildungslandschaft zu sein. Gleichwohl könnten Governance Schools als Hochschulen mit großer Autonomie als Impulsgeber in der gegenwärtigen Reformdiskussion fungieren. Hinsichtlich der möglichen Effekte auf die Elitenrekrutierung sollten Governance Schools angesichts des derzeitigen Standes der Zugangsstrukturen insbesondere zu öffentlichen Leitungspositionen in Deutschland nicht dramatisiert werden. Statt der befürchteten, selbstreferentiellen Abschottung politischer Eliten mit homogenen Ausbildungshintergrund können sie u.U. sogar dem Leistungsprinzip Vorschub leisten, dass sowohl unter Effektivitäts- als auch unter Legitimitätsgesichtspunkten zu einer Verbesserung gegenüber dem Status quo führt. Angesichts der noch immer in den meisten Bereichen existierenden Juristendominanz und der zentralen Rolle der Parteien in der Elitenrekrutierung wollen „Governance Schools“ in Deutschland zunächst andere Vereinseitigungen der politischen Elitenrekrutierung aufbrechen. Der Blick auf die negativen Auswüchse von „Schulen der Macht“ in anderen Ländern Europas macht gleichwohl deutlich, dass erstens eine Umkehrung der Verhältnisse im Sinne eines fast vollständigen Monopols der Elitenausbildung durch entsprechende Einrichtungen nicht wünschenswert sein kann und dass zweitens den Aufnahmeverfahren besondere Aufmerksamkeit zu widmen ist, um den Offenheitsanspruch des Leistungsprinzips in der Elitenrekrutierung aufrecht zu erhalten

The Bass functional of martingale transport

An interesting question in the field of martingale optimal transport, is to determine the martingale with prescribed initial and terminal marginals which is most correlated to Brownian motion. Under a necessary and sufficient irreducibility condition, the answer to this question is given by a $\textit{Bass martingale}$. At an intuitive level, the latter can be imagined as an order-preserving and martingale-preserving space transformation of an underlying Brownian motion starting with an initial law $\alpha$ which is tuned to ensure the marginal constraints. In this article we study how to determine the aforementioned initial condition $\alpha$. This is done by a careful study of what we dub the $\textit{Bass functional}$. In our main result we show the equivalence between the existence of minimizers of the Bass functional and the existence of a Bass martingale with prescribed marginals. This complements the convex duality approach in a companion paper by the present authors together with M. Beiglb\"ock, with a purely variational perspective. We also establish an infinitesimal version of this result, and furthermore prove the displacement convexity of the Bass functional along certain generalized geodesics in the $2$-Wasserstein space

Psychophysiology of False Memories in a Deese-Roediger-McDermott Paradigm with Visual Scenes

Remembering something that has not in fact been experienced is commonly referred to as false memory. The Deese-Roediger-McDermott (DRM) paradigm is a well-elaborated approach to this phenomenon. This study attempts to investigate the peripheral physiology of false memories induced in a visual DRM paradigm. The main research question is whether false recognition is different from true recognition in terms of accompanying physiological responses

Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)

Background: Treatment of spasticity poses a major challenge in amyotrophic lateral sclerosis (ALS) patient management. Delta-9-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (THC:CBD), approved for the treatment of spasticity in multiple sclerosis, serves as a complementary off-label treatment option in ALS-related spasticity. However, few structured data are available on THC:CBD in the treatment of spasticity in ALS. Method: A retrospective mono-centric cohort study was realised in 32 patients that meet the following criteria: 1) diagnosis of ALS, 2) ALS-related spasticity; 3) treatment with THC:CBD. Spasticity was rated using the Numeric Rating Scale (NRS). Patient’s experience with THC:CBD was assessed using the net promoter score (NPS) and treatment satisfaction questionnaire for medication (TSMQ-9) as captured through telephone survey or online assessment. Results: The mean dose THC:CBD were 5.5 daily actuations (range<1 to 20). Three subgroups of patients were identified: 1) high-dose daily use (≥ 7 daily actuations, 34%, n = 11), 2) low-dose daily use (< 7 daily actuations, 50%, n = 16), 3) infrequent use (< 1 daily actuation, 16%, n=5). Overall NPS was + 4.9 (values above 0 express a positive recommendation to fellow patients). Remarkably, patients with moderate to severe spasticity (NRS ≥ 4) reported a high recommendation rate (NPS: +29) in contrast to patients with mild spasticity (NRS<4; NPS: − 44). For the three main domains of TSQM-9 high mean satisfaction levels were found (maximum value 100): effectiveness 70.5 (±22.3), convenience 76.6 (±23.3) and global satisfaction 75.0 (±24.7). Conclusion: THC:CBD is used in a wide dose range suggesting that the drug was applied on the basis of individual patients’ needs and preferences. Contributing to this notion, moderate to severe spasticity was associated with an elevated number of daily THC:CBD actuations and stronger recommendation rate (NPS) as compared to patients with mild spasticity. Overall, treatment satisfaction (TSQM-9) was high. The results suggest that THC:CBD may serve as a valuable addition in the spectrum of symptomatic therapy in ALS. However, prospective studies and head-to-head comparisons to other spasticity medications are of interest to further explore the effectiveness of THC:CBD in the management of spasticity, and other ALS-related symptoms

Orthorexia nervosa: A behavioral complex or a psychological condition?

Background and aims: Numerous studies have provided evidence for orthorexia nervosa (ON), an eating pattern characterized by an almost manic obsession for and fixation on healthy eating, to be of epidemiological relevance. However, there is scientific debate on whether it is merely a behavioral or lifestyle phenomenon as compared to a mental disorder. Aim of this cross-sectional study was to explore whether ON is of epidemiological and clinical relevance, and whether ON can be distinguished from other mental health disorders and healthy lifestyle features. Methods: An online survey including a measure of orthorexic behaviors [Duesseldorf Orthorexia Scale (DOS)], well-being and distress, eating behaviors, pathological eating, anxiety and depression, addictive behaviors, obsessive–compulsive symptoms, personality, and health behaviors was completed by 713 subjects (79.8% women, 18–75 years, median age: 25 years). Results: Twenty-seven subjects (3.8%, 21 women) showed significant orthorexic eating (DOS ≥ 30). ON cases reported lower well-being, lower satisfaction with life, and higher current stress levels than non-ON cases. The highest percentage of variation in ON was explained by pathological eating (R2 = .380), followed by eating style, Mediterranean diet, compulsive symptoms, and subjective social status. Importantly, ON provided hardly any additional predictive value for well-being when also considering pathological eating. Discussion and conclusions: Our data confirmed the epidemiological and clinical relevance of orthorexic behaviors, but the strong conceptual overlap with other mental health problems and pathological eating raise initial doubts as to whether ON is a distinct mental health disorder category. This co-occurrence, unique symptoms, and underlying processes need further exploration by comparing ON cases with patients with other mental disorders

Non‐invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany

Background and purpose: The aim of this study was to investigate utilization rates, treatment pathways and survival prognosis in patients with amyotrophic lateral sclerosis (ALS) undergoing non-invasive (NIV) and tracheostomy invasive ventilation (TIV) in a real-world setting. Methods: A prospective cohort study using a single-centre register of 2702 ALS patients (2007 to 2019) was conducted. Utilization of NIV/TIV and survival data were analysed in three cohorts: (i) non-NIV; (ii) NIV (NIV without subsequent TIV); and (iii) TIV (including TIV preceded by NIV). Results: A total of 1720 patients with available data were identified, 72.0% of whom (n = 1238) did not receive ventilation therapy. NIV was performed in 20.8% of patients (n = 358). TIV was performed in 9.5% of patients (n = 164), encompassing both primary TIV (7.2%, n = 124) and TIV with preceding NIV (2.3%, n = 40). TIV was more often utilized without previous NIV (25.7% vs. 8.3% of all ventilated patients), demonstrating that primary TIV was the prevailing pathway for invasive ventilation. The median (range) survival was significantly longer in the NIV cohort (40.8 [37.2–44.3] months) and the TIV cohort (82.1 [68.7–95.6] months) as compared to the non-NIV cohort (33.6 [31.6–35.7] months). Conclusions: Although NIV represents the standard of care, its utilization rate was low. TIV was mainly started without preceding NIV, suggesting that TIV may not be confined to NIV treatment escalation. However, TIV was pursued in a minority of patients who had previously undergone NIV. The survival benefit observed in the patients with NIV was equal to that reported in a controlled pivotal trial, but the prognosis with TIV is highly variable. The determinants of utilization of NIV/TIV and of survival (bulbar syndrome, availability of ventilation-related home nursing, cultural factors) warrant further investigation

Virtual testing of multifunctional moveable actuation systems

This work presents the current state of the virtual testing activities performed within the Virtual Product House (VPH) start-up project. In this project a multidisciplinary, collaborative end-to-end process for virtual product design is developed. On the basis of preliminary design and concept studies on aircraft level, the process focusses on design, manufacturing and testing of aircraft systems and structural components with special attention to certification aspects. The initial use case considers the trailing edge flap of a long-range aircraft and its actuation system. Design and analysis tools are integrated in a remote workflow execution environment to automatically generate designs and evaluate them by virtual test means. Virtual tests facilitate knowledge on properties and behavior of the virtual product in early development phases and allow to optimize design flaws in consecutive design iterations to hence reduce the risk of costly corrections later in the development process. The testing is setup in multiple stages. Currently, domain-specific tests are carried out for the moveable structure and its actuation system, with the latter being in focus for the current text. These tests address the functional verification of the actuation system in nominal and failure cases. A SysML model comprising system requirements and architecture is used to model test cases and trace test results. On the basis of these test cases, simulation configurations for virtual tests are automatically built, executed and evaluated. With this method, a continuous evaluation of designs in terms of functional verification of the moveable actuation system is possible. Moreover, the automated execution of all steps allows to determine the effects of design changes quickly without a large amount of labor-intensive and error-prone work

PrPSc spreading patterns in the brain of sheep linked to different prion types

Scrapie in sheep and goats has been known for more than 250 years and belongs nowadays to the so-called prion diseases that also include e.g. bovine spongiform encephalopathy in cattle (BSE) and Creutzfeldt-Jakob disease in humans. According to the prion hypothesis, the pathological isoform (PrPSc) of the cellular prion protein (PrPc) comprises the essential, if not exclusive, component of the transmissible agent. Currently, two types of scrapie disease are known - classical and atypical/Nor98 scrapie. In the present study we examine 24 cases of classical and 25 cases of atypical/Nor98 scrapie with the sensitive PET blot method and validate the results with conventional immunohistochemistry. The sequential detection of PrPSc aggregates in the CNS of classical scrapie sheep implies that after neuroinvasion a spread from spinal cord and obex to the cerebellum, diencephalon and frontal cortex via the rostral brainstem takes place. We categorize the spread of PrPSc into four stages: the CNS entry stage, the brainstem stage, the cruciate sulcus stage and finally the basal ganglia stage. Such a sequential development of PrPSc was not detectable upon analysis of the present atypical/Nor98 scrapie cases. PrPSc distribution in one case of atypical/Nor98 scrapie in a presumably early disease phase suggests that the spread of PrPSc aggregates starts in the di- or telencephalon. In addition to the spontaneous generation of PrPSc, an uptake of the infectious agent into the brain, that bypasses the brainstem and starts its accumulation in the thalamus, needs to be taken into consideration for atypical/Nor98 scrapie

Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential

El pdf del artículo es el manuscrito de autor.-- PubMed: PMCID:PMC2670444Cathepsins have been best characterized in tumorigenesis and cell death and implicated in liver fibrosis; however, whether cathepsins directly regulate hepatic stellate cell (HSC) activation and proliferation, hence modulating their fibrogenic potential, is largely unknown. Here, we show that expression of cathepsin B (CtsB) and cathepsin D (CtsD) is negligible in quiescent HSCs but parallels the increase of -smooth muscle actin and transforming growth factor- during in vitro mouse HSC activation. Both cathepsins are necessary for HSC transdifferentiation into myofibroblasts, because their silencing or inhibition decreasedHSC proliferation and the expression of phenotypicmarkers ofHSC activation, with similar results observed with the human HSC cell line LX2. CtsB inhibition blunted AKT phosphorylation in activated HSCs in response to platelet-derived growth factor.Moreover, during in vivo liver fibrogenesis caused by CCl4 administration, CtsB expression increased in HSCs but not in hepatocytes, and its inactivation mitigated CCl4-induced inflammation, HSC activation, and collagen deposition. Conclusion: These findings support a critical role for cathepsins inHSC activation, suggesting that the antagonismof cathepsins inHSCsmay be of relevance for the treatment of liver fibrosis.Financial support: The work was supported by CIBEREHD and grant PI070193 (Instituto de Salud Carlos III); by grant SAF2006-06780 (Plan Nacional de I+D), Spain; and by grant P50-AA-11999 (Research Center for Liver and Pancreatic Diseases, US National Institute on Alcohol Abuse and Alcoholism).Peer reviewe